N@N

Pulte Homes Inc. 7.375% Senior Notes due June 1 2046 (NYSE:PHA), Down By 5.19% ($1.11) From $21.370 After BUYINS.NET Report Pre

^{Published on 2011-08-19 13:28:39 - WOPRAI}
 

August 19, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Saturday, August 13th 2011 stating that Pulte Homes Inc. 7.375% Senior Notes due June 1 2046 (NYSE:PHA) was expected to go Down due to the Bearish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/tools/symbol_stats.php?sym=pha

At the time this story was written, Pulte Homes Inc. 7.375% Senior Notes due June 1 2046 (NYSE:PHA) is Down By $1.11 (5.19%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Pulte Homes Inc. 7.375% Senior Notes due June 1 2046 (NYSE:PHA) - Pharmacia Corporation, formed in 2000, is primarily involved in the development, manufacturing and sale of pharmaceutical products. Prescription pharmaceuticals is the Company's only business segment and includes general therapeutics, ophthalmology and hospital products, including oncology and diversified therapeutics. The Company also operates several business units that do not constitute reportable business segments. These operating units include, among others, consumer healthcare, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. Due to the size of these operating units, they have been grouped into the Other Pharmaceuticals category. The Company's products are sold throughout the world to a wide range of customers, including pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. In April 2003, the Company completed its merger with and into Pfizer. Pharmacia and Pfizer's combined operations create a research-based pharmaceutical company.

Prescription Pharmaceuticals

The Company's leading prescription products include Celebrex, Xalatan, Genotropin, Camptosar, Detrol LA and Zyvox. Celebrex, a cyclooxygenase-2 (COX-2) specific inhibitor, is a nonsteroidal anti-inflammatory drug, and is used for the treatment of osteoarthritis, adult rheumatoid arthritis, acute pain and primary dysmenorrhea. Celebrex is available in over 70 countries and is co-promoted (or, where required by law, co-marketed) by Pfizer, Inc. in the United States and Europe, and will be co-promoted by Yamanouchi when approved in Japan.

Xalatan, the Company's branded intraocular pressure (IOP) lowering agent, is used in the treatment of open-angle glaucoma and ocular hypertension in patients insufficiently controlled on other medications. During 2001, Xalacom, a fixed combination of Xalatan and the beta-blocker timolol, was approved in Sweden and the European Union, where it is marketed under the name Xalacom. The Company continues to seek approval of Xalcom in the United States after receiving a third approvable letter from the Food and Drug Administration (FDA). Xalcom provides a greater reduction in intraocular pressure.

Genotropin, a recombinant human growth hormone, is used to treat adults with growth hormone deficiency and to treat growth failure in children with growth hormone deficiency. In 2000, Genotropin was also approved for the treatment of growth failure in children with Prader-Willi Syndrome (PWS), and in 2001, it was approved for use with children who were born small for gestational age (SGA) who have not caught up in growth by age two. Genotropin has been granted orphan drug status by the FDA for both PWS and SGA. Adding to the Company's endocrine treatment business, in early 2001, it completed its acquisition of Sensus Drug Development Corporation, which filed a New Drug Application (NDA) with the FDA for pegvisomant, a growth hormone receptor antagonist. Pegvisomant is being reviewed for the treatment of acromegaly, a life-threatening disorder caused by overproduction of growth hormone.

Camptosar, a first-line therapy in metastatic colorectal cancer, is a treatment for colorectal cancer. The product was in-licensed from Yakult Honsha Co. for marketing in the United States. In addition to Camptosar, the Company markets several other oncology drugs. Pharmorubicin is a commonly used treatment for breast cancer in Europe, and is marketed under the trade name Ellence in the United States for the adjuvant treatment of patients with breast cancer. Aromasin, an oral hormonal drug that blocks the production of estrogen, was launched during 2000 in the United States and in key markets in Europe and Latin America as a second-line breast cancer treatment. The Company's subsidiary, Sugen, Inc., has developed proprietary technology platforms to identify small molecule drugs that target specific cellular signal transduction pathways and may have oncological or other therapeutic uses. Pharmacia announced, on February 8, 2002, that it was closing its SU541

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net